Last reviewed · How we verify
Biologic therapy for psoriasis
At a glance
| Generic name | Biologic therapy for psoriasis |
|---|---|
| Also known as | Anti-TNF, Anti-IL-12/23, Anti-IL-17, Anti-IL-23 |
| Sponsor | Juan Ruano Ruiz |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Impact of Clinical and Psychological Factors on Satisfaction With Treatment in Psoriatic Patients on Biological Therapy
- Psoriasis Longitudinal Assessment and Registry
- Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease
- Modifying PEST for Psoriatic Arthritis Screening (NA)
- Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
- SEquential Treatment of PSoriasis With Biologics
- A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa (PHASE2)
- Role of Reverse Transcriptase Inhibitors in the Treatment of Psoriasis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |